Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Mead Johnson Nutrition CO (MJN), Boston Scientific Corporation (BSX), And 2 Other Stocks Might Be Right For Your Portfolio

Blue Jay Capital Management sold 15% of its ABIOMED, Inc. (NASDAQ:ABMD) shares during the second quarter, ending the period with 104,920 shares of the company, whose total worth was over $11.46 million at the end of June. ABIOMED’s shares delivered a return of 17.7% in the three-month period ended September 30. Heading into the third quarter of 2016, a total of 29 of the hedge funds tracked by Insider Monkey were bullish on this stock, 21% higher than from the previous quarter. Palo Alto Investors was the largest shareholder of ABIOMED, Inc. (NASDAQ:ABMD), with a stake worth $225.9 million reported as of the end of June. Trailing Palo Alto Investors was Renaissance Technologies, which amassed a stake valued at $67.9 million. Sectoral Asset Management, Arrowstreet Capital, and Polar Capital were other shareholders of the company.

Follow Abiomed Inc (NASDAQ:ABMD)
Trade (NASDAQ:ABMD) Now!

Boston Scientific Corporation (NYSE:BSX) was a new pick of Blue Jay Capital in the second quarter, as the fund acquired 469,900 Class A shares of the company, with those shares being worth $10.98 million at the end of June. The stock however returned a scant 1.8% during the third quarter, so this was one of the fund’s rare underperforming picks. Blue Jay was one of many hedge funds in our system to jump into the stock in Q2. BSX was in 47 hedge funds’ portfolios at the end of June, up from just 35 at the end of the previous quarter. OrbiMed Advisors was the largest shareholder of Boston Scientific Corporation (NYSE:BSX), with a stake worth $540.5 million reported as of the end of June. Trailing OrbiMed Advisors was Citadel Investment Group, which amassed a stake valued at $343.4 million. Millennium Management, Renaissance Technologies, and Diamond Hill Capital also held valuable positions in the company.

Follow Boston Scientific Corp (NYSE:BSX)
Trade (NYSE:BSX) Now!

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.